PEPIN RONALD 4

What Happened

• Ronald Pepin, Senior Vice President and Chief Business Officer of Celldex Therapeutics (CLDX), was granted a derivative award on 2026-06-25 covering 20,000 shares. The reported acquisition price is $0.00, indicating a stock option-type award rather than an open-market purchase or sale. No shares were sold or exercised in this filing.

Key Details

• Transaction date: 2026-06-25; Form filed: 2026-06-29 (timely filing).
• Transaction type: Award/Grant (derivative). Reported amount: 20,000 shares at $0.00.
• Vesting: 25% vests on June 25, 2027; the remainder vests in equal quarterly installments over the following 12 quarters. (Footnote: award granted under the Issuer’s 2021 Omnibus Equity Incentive Plan.)
• Shares owned after the transaction: not specified in the information provided in this summary.
• Filing timeliness: filed within the SEC’s Form 4 reporting window (not marked late).

Context

• This was a compensation-related option award (future equity) rather than a market purchase or sale. Such grants are common for executives and represent potential future ownership if vesting and any exercise conditions are met — they do not indicate an immediate cash transaction or market sentiment.